MedTrace Logo

Dopaminergic Mechanism of Memory Impairment in Parkinson's Disease

NCT04968613 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2021-07-20

No results posted yet for this study

Summary

The cognitive impairment of Parkinson's disease is non amnestic, which is characterized by working memory impairment and executive dysfunction. The current drug therapy (such as levodopa, dopamine receptor agonists) and surgical treatment (such as deep brain electrical stimulation, thalamic lesion) not only can not effectively alleviate cognitive impairment, but also may aggravate cognitive and speech behavior abnormalities. This project will explore how dopamine regulates temporal working memory in human research by combining drug intervention, neuroimaging and cognitive tasks.

Conditions

  • Parkinson Disease
  • Memory Impairment

Interventions

DRUG

Madopar monotherapy

In addition to basic treatment, the patient also received Madopar treatment

DRUG

senfrol monotherapy

In addition to the basic treatment, the patient also received the rofosson treatment

DRUG

placebo monotherapy

In addition to basic treatment, the patient also received selegiline treatment

Sponsors & Collaborators

  • Chinese Academy of Sciences

    collaborator OTHER_GOV

  • Peking University Third Hospital

    lead OTHER

Principal Investigators

  • Yingshuang Zhang · Peking University Third Hospital

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04968613 on ClinicalTrials.gov